ReviewJournal of medicinal chemistry2026
Mass Spectrometry Proteomics: A Key to Faster Drug Discovery.
Review in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Advances in proteomics research related to semaglutide: evidence from humans and animals.Journal of endocrinological investigation · 2026Review
- Review
- Robotic perturbation proteomics and AI agents enable scalable drug mechanism discovery.bioRxiv : the preprint server for biology · 2026Article
- Computational proteomics to enhance personalized treatment of COVID-19 and Long COVID.Clinical proteomics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mass spectrometry (MS)-based proteomics is a disruptive platform in drug discovery that offers an exhaustive view of the proteome's complexity. Focusing on bottom-up MS proteomics, this technology enables high-throughput analysis of protein expression, interactions, and modifications, far surpassing the capabilities of traditional single-protein methods. The MS proteomics toolbox is essential in both early- and late-stage development of new drugs. The techniques discussed here, such as unlabeled and labeled proteomics and chemoproteomic approaches (e.g., thermal proteome profiling and photoaffinity labeling), facilitate target binding site exploration and the identification of putative off-targets. By accelerating the identification of new druggable proteins and supporting early biomarker discovery, MS proteomics significantly accelerates the preclinical-to-clinical transition. Ongoing progress in data acquisition, new computational tools, and artificial intelligence further enhances the high-throughput properties of these approaches, marking a significant step toward personalized medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.